Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003822 · ClinicalTrials.gov registry record · Phase 1
SR-45023A in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003822 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 30 participants.
The verdict
NCT00003822, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have advanced solid tumors.
Interventions
- DRUG apomine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003822
The ClinicalTrials.gov registry entry for NCT00003822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apomine is the first listed.
NCT00003822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003822 about?
NCT00003822 is a clinical study titled "SR-45023A in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have advanced solid tumors.
What is the current status of trial NCT00003822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1998-08.
What interventions are being tested in trial NCT00003822?
The interventions under investigation include: apomine (DRUG).
Who is sponsoring clinical trial NCT00003822?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.